The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kazia Therapeutics’ (NASDAQ:KZIA) Paxalisib for the treatment of atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly-aggressive childhood brain cancer.
Paxalisib is being investigated in a phase II clinical trial of multiple drug therapies, under the sponsorship of the Pacific Pediatric Neuro-Oncology Consortium (PNOC).
